Butyrate Treatment of DSS-Induced Ulcerative Colitis Affects the Hepatic Drug Metabolism in Mice

Jourová, L.; Satka, S.; Frýbortová, V.; Zapletalová, I.; Anzenbacher, P.; Anzenbacherová, E.; Hermanová, Petra; Draboňová, Barbora; Šrůtková, Dagmar; Kozáková, Hana; Hudcovic, Tomáš

doi:https://dx.doi.org/10.3389/fphar.2022.936013

Number of the records: 1

Butyrate Treatment of DSS-Induced Ulcerative Colitis Affects the Hepatic Drug Metabolism in Mice

1.

SYSNO ASEP	0559852
Document Type	J - Journal Article
R&D Document Type	Journal Article
Subsidiary J	Článek ve WOS
Title	Butyrate Treatment of DSS-Induced Ulcerative Colitis Affects the Hepatic Drug Metabolism in Mice
Author(s)	Jourová, L. (CZ) Satka, S. (CZ) Frýbortová, V. (CZ) Zapletalová, I. (CZ) Anzenbacher, P. (CZ) Anzenbacherová, E. (CZ) Hermanová, Petra (MBU-M)_ORCID Draboňová, Barbora (MBU-M) Šrůtková, Dagmar (MBU-M)_{ORCID, RID} Kozáková, Hana (MBU-M)_{RID, ORCID} Hudcovic, Tomáš (MBU-M)_{RID, ORCID}
Article number	936013
Source Title	Frontiers in Pharmacology. - : Frontiers Media - ISSN 1663-9812 Roč. 13, JUL 19 2022 (2022)
Number of pages	14 s.
Language	eng - English
Country	CH - Switzerland
Keywords	gut-liver axis ; butyrate ; gut inflammation ; drug metabolism ; cytochromes P450
Subject RIV	FR - Pharmacology ; Medidal Chemistry
OECD category	Pharmacology and pharmacy
R&D Projects	GA19-08294S GA ČR - Czech Science Foundation (CSF)
Method of publishing	Open access
Institutional support	MBU-M - RVO:61388971
UT WOS	000835075500001
EID SCOPUS	85135203890
DOI	10.3389/fphar.2022.936013
Annotation	The development of inflammatory bowel disease (IBD) is associated with alterations in the gut microbiota. There is currently no universal treatment for this disease, thus emphasizing the importance of developing innovative therapeutic approaches. Gut microbiome-derived metabolite butyrate with its well-known anti-inflammatory effect in the gut is a promising candidate. Due to increased intestinal permeability during IBD, butyrate may also reach the liver and influence liver physiology, including hepatic drug metabolism. To get an insight into this reason, the aim of this study was set to clarify not only the protective effects of the sodium butyrate (SB) administration on colonic inflammation but also the effects of SB on hepatic drug metabolism in experimental colitis induced by dextran sodium sulfate (DSS) in mice. It has been shown here that the butyrate pre-treatment can alleviate gut inflammation and reduce the leakiness of colonic epithelium by restoration of the assembly of tight-junction protein Zonula occludens-1 (ZO-1) in mice with DSS-induced colitis. In this article, butyrate along with inflammation has also been shown to affect the expression and enzyme activity of selected cytochromes P450 (CYPs) in the liver of mice. In this respect, CYP3A enzymes may be very sensitive to gut microbiome-targeted interventions, as significant changes in CYP3A expression and activity in response to DSS-induced colitis and/or butyrate treatment have also been observed. With regard to medications used in IBD and microbiota-targeted therapeutic approaches, it is important to deepen our knowledge of the effect of gut inflammation, and therapeutic interventions were followed concerning the ability of the organism to metabolize drugs. This gut-liver axis, mediated through inflammation as well as microbiome-derived metabolites, may affect the response to IBD therapy.
Workplace	Institute of Microbiology
Contact	Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231
Year of Publishing	2023
Electronic address	https://www.frontiersin.org/articles/10.3389/fphar.2022.936013/full

Number of the records: 1